ClinicalTrials.gg
CompletedNCT01509365PLATO-doseUpdated May 7, 2015

Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27

A Phase 4 interventional study of clopidogrel and clopidogrel in Cardiovascular Disease and Overweight, sponsored by Les Laboratoires des Médicaments Stériles. Completed at 1 site in Tunisia. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-05-07.

Sponsored by Les Laboratoires des Médicaments Stériles · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

The purpose of the study is to determine whether administration of 150 mg clopidogrel is effective in reducing the one-year incidence of thromboischemic events in patients with high on-clopidogrel platelet reactivity compared to 75 mg clopidogrel in the patient population overweight or obese with a body mass index (BMI) ≥ 27 kg.m-2.

Read the detailed description

The goal is to evaluate the effect of the double maintenance dose of clopidogrel versus single dose in patients with proven coronary and with BMI ≥ 27 kg.m-2 1 - Biologically: study and compare the respective effects of the double dose and single dose of clopidogrel on platelet aggregation.

2 - Clinically: to study and compare the cardiovascular events and adverse effects depending on the dose of clopidogrel.

02

Conditions studied

  • Cardiovascular Disease
  • Overweight

Keywords

  • cardiovascular disease
  • maintenance dose
  • clopidogrel
  • overweight
  • antiplatelet agents
03

In context

Cardiovascular Diseases

5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.

This study's enrollment of 116 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Les Laboratoires des Médicaments Stériles is the lead sponsor of 13 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female,
  • Old (e) of more than 20 years
  • ≥ 27kg.m-2
  • Patients hospitalized for acute coronary syndrome (Whatever the ST segment and troponin dosage)
  • Patients with proven coronary candidates for treatment with Clopidogrel (who received a loading dose of 600mg over 2 hours or treated with 75 mg/day or 150mg / day of clopidogrel for longer than 7 days)

Exclusion criteria

Exclusion Criteria:

  • Patients unwilling.
  • Patient participating in another study.
  • Patients with cardiogenic shock
  • Patient on anti GpIIbIIIa or stopped less than 72 hours before the test aggregability
  • Patients scheduled for surgery in less than 6 months
  • ischemic stroke older than 6 weeks.
  • History of hemorrhagic stroke (any time)
  • Patients on or candidates for AVK
  • Patients with a different anti ADP (ticlopidine, prasugrel)
  • Patients with an indication against clopidogrel (side effects, bleeding ...)
  • Thrombocytopenia \< 100000/mm3
  • anemia (Ht \< 30%)
  • Thrombocythaemia (Ht > 52%)
  • Pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (actual)

Study arms

  • No intervention
    sensible

    Patients who show adequate response to loading dose of clopidogrel and receive standard 1x75 mg clopidogrel for at least 7 days.

  • Active comparator
    simple dose

    Patients who show suboptimal response to loading dose of clopidogrel and receive 1x75 mg clopidogrel for 1 month followed by standard 75 mg clopidogrel for 3 months to one year.

    Drug: clopidogrel

  • Experimental
    double dose

    Patients who show suboptimal response to loading dose of clopidogrel and receive 1x150 mg clopidogrel for 1 month followed by standard 75 mg clopidogrel for 3 months to one year.

    Drug: clopidogrel

Interventions

  • 2 tablets of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.

  • 1 tablet of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.

06

What researchers measure

Primary outcomes

  1. Cardiac death or non-fatal myocardial infarction or ischemia-driven target vessel revascularisation

    Time frame: 6 months

Secondary outcomes

  1. ADP-induced platelet aggregation assessed by VerifyNow test

    Time frame: 7 days after selection of patients

07

Study locations

1 site
  • cardiology department, hospital Fattouma Bourguiba
    Monastir, 5000, Tunisia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Feb 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2012
First posted
Jan 13, 2012
Start
Dec 2011
Primary completionActual
Feb 2015
CompletionActual
May 2015
Last update
May 7, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01509365
Lead sponsor
Les Laboratoires des Médicaments Stériles
Collaborators
University Hospital Fattouma Bourguiba
Responsible party
Sponsor
First posted
Jan 13, 2012
Start date
Dec 2011
Primary completion
Feb 2015
Completion
May 2015
Last update
May 7, 2015

Study contacts

Faouzi Maatouk, MD
study chair · hospital Fattouma Bourguiba
Khaldoun Ben Hamda, MD
principal investigator · Hospital Fattouma Bourguiba
Sonia Hamdi, MD
principal investigator · Hospital Fattouma Bourguiba
Mohsen Hassine
principal investigator · Hospital Fattouma Bourguiba

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clopidogrel

Start the discussion